Evaluation of Gixam's Efficacy Predicting the Presence of Advanced and Non-advanced Colorectal Neoplasia in a FIT Negative Population

Recruiting now · Not applicable

Conditions studied: CRC Screening, Microbiome

In brief

The goal of this clinical trial is to learn if the Gixam device effectively identifies persons with pre-cancer or cancer in the colon and rectum in adults aged 45-84 that are of average risk to develop colorectal cancer and have received a negative result on a Fecal Immunochemical Test (FIT). The main questions it aims to answer are: 1. Is the Gixam Device effective in identifying persons with pre-cancer or cancer in the colon and rectum that have received a negative FIT result? 2. Is the use of the Gixam device safe? Gixam test result will be compared to the findings of a standard of care screening colonoscopy. Study participants will: 1. Undergo the Gixam test 2. Take a FIT at home and ship to a laboratory. 3. Undergo a standard of care screening colonoscopy.

Key facts

Study ID

NCT07623902

Run by

Jubaan Ltd.

People needed

1436

Starts

2026-05-18

Expected to finish

2026-12-31

Last updated by the study team

2026-06-03

Who can join

Age: 45 and older, up to 84. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants aged ≥45 - ≤84 years.
• Able to provide a signed informed consent.
• Considered by a physician or healthcare provider as being of 'average risk' for CRC.
• Scheduled for a screening colonoscopy at investigation site.

You may not qualify if…

• Undergoing colonoscopy for investigation of symptoms.
• Has undergone colonoscopy within preceding nine (9) years except for a failed colonoscopy due to poor bowel preparation. Failed colonoscopy must have been within the past year and without therapeutic intervention.
• Positive FIT or Fecal Occult Blood Test (FOBT) result within the preceding eleven (11) months.
• Has completed Cologuard, Sheild, ColoSense or Epi proColon testing within the preceding three (3) years.
• History of colorectal cancer.
• Family history of colorectal cancer, defined as having one or more first- degree relatives (parent, sibling, or child) with CRC at any age.
• Participant has a diagnosis or medical / family history of any of the following conditions, including:
• Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP and Gardner's syndrome)
• Hereditary non-polyposis CRC syndrome (also referred to as "HNPCC" or "Lynch Syndrome")
• Other hereditary cancer syndromes including but not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Neurofibromatosis, or Familial Hyperplastic Polyposis.
• Participant has a diagnosis or personal history of inflammatory bowel disease (IBD) including chronic ulcerative colitis and/or Crohn's disease.
• Participants with a disability to extend their tongue.
• Participants with tongue tremor.
• Participants with tongue piercing.
• Participants that had a dental visit in the 7 days prior to the Gixam test.
• Participants that have taken antibiotics or anti-fungal medications in the 14 days prior to the Gixam test.
• Participants that have taken anti-inflammatories or probiotics in the 14 days prior to the Gixam test.
• Participant is pregnant.
• Participant has any condition that in the opinion of the Investigator should preclude participation in the study.

Where it is running

• Orlando Gastroenterology, PA — Orlando, Florida, United States (enrolling)
• Comprehensive Gastrointestinal Health, LLC — Northbrook, Illinois, United States (enrolling)
• Westchester Putnam Gastro — Carmel, New York, United States (enrolling)
• Great Lakes Gastroenterology Research, LLC — Mentor, Ohio, United States (enrolling)
• Blue Ridge Medical Research — Lynchburg, Virginia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.